COVID-19 infection-induced type one Diabetes Mellitus and Diabetic Ketoacidosis
Abstract
A 63 year old female patient presented with one week history of reduced appetite, weakness, nausea, polyuria and occasional vomiting on a back ground of recurrent urinary tract infection and hypothyroidism. She appeared lethargic and dehydrated. The arterial blood gas showed a picture of diabetic ketoacidosis (DKA) which was treated according to the protocol. Viral polymerase chain reaction (PCR) for COVID-19 was positive. The diagnosis of new onset type one diabetes made on the basis of specific antibodies test. Computerized Tomography (CT) of abdomen excluded pancreatic cancer as a cause of new onset diabetes. Hence, the patient was labelled as type one diabetes mellitus induced by COVID-19 virus. She was treated accordingly and sent home on insulin. Follow-up appointment was arranged in the diabetes center of the hospital.
References
2. Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020. https://doi.org/10.1177/1932296820924469
3. Chee YJ, Ng SJH, Yeoh E. Diabetic ketoacidosis precipitated by Covid‐19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract. 2020;164:108166. https://doi.org/10.1016/j.diabres.2020.108166
4. Heaney AI, Griffin GD, Simon EL. Newly diagnosed diabetes and diabetic ketoacidosis precipitated by COVID‐19 infection. Am J Emerg Med. 2020. https://doi.org/10.1016/j.ajem.2020.05.114
5. Zhang Y.Z., Holmes E.C. A genomic perspective on the origin and emergence of sars-cov-2. Cell. 2020;181(2):223–227. [PMC free article] [PubMed] [Google Scholar]
6. Federation ID. COVID-19 outbreak: guidance for people with diabetes. International Diabetes Federation; 2020. https://www.idf.org/aboutdiabetes/what-is-diabetes/covid-19-and-diabetes/1-covid-19-and-diabetes.html
7. Hu L, Chen S, Fu Y, Gao Z, Long H, Ren H-W et al. Risk factors associated with clinical outcomes in 323 COVID-19 patients in Wuhan, China. medRxiv; 2020. [PMC free article] [PubMed]
8. 57. Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 doi: 10.1038/s41569-020-0360-5. Epub 2020/03/07. Epub 2020/03/07. PubMed PMID: 32139904. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Fadini G.P., Morieri M.L., Longato E., Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020 doi: 10.1007/s40618-020-01236-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
10. Yang W, Cai X, Han X, Ji L. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2016;32:391–404. https://doi.org/10.1002/dmrr.2723.
11. ClinicalTrials.gov . 2020. Effects of DPP4 Inhibition on COVID-19.https://clinicaltrials.gov/ct2/show/NCT04341935 [Google Scholar]
12 . Pradhan A, Vohra S, Vishwakarma P, et al. Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure. J Family Med Prim Care. 2019 June;8(6);1855- 1862.
Copyright (c) 2021 Amir Hayat, Sohail Siddique, Syed Rehan Shamim
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All research articles published in the Journal of Rawalpindi Medical College (JRMC) are fully open access: immediately freely available to read, download, and share. Copyrights of all articles published in JRMC are retained by the authors. First publication rights are granted to JRMC. The journal/publisher is not responsible for subsequent uses of the work.
All articles are published under the Creative Commons Attribution (CC BY-SA 4.0) license.
